Home
Ernst Asbjørn Lien's picture

Ernst Asbjørn Lien

Emeritus
  • E-mailernst.lien@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2020). First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: A case study. ESMO Open. 1-5.
  • Show author(s) (2019). Drug monitoring of tamoxifen metabolites predicts vaginal dryness and verifies a low discontinuation rate from the Norwegian Prescription Database. Breast Cancer Research and Treatment. 185-195.
  • Show author(s) (2017). Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Research.
  • Show author(s) (2016). A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen. Breast Cancer Research and Treatment. 97-108.
  • Show author(s) (2015). The active tamoxifen metabolite endoxifen (4OHNDtam) strongly down-regulates cytokeratin 6 (CK6) in MCF-7 breast cancer cells. PLOS ONE. 19 pages.
  • Show author(s) (2015). Novel inflammatory biomarkers in primary hyperparathyroidism. European Journal of Endocrinology (EJE). 9-17.
  • Show author(s) (2014). Illness uncertainty in breast cancer patients: Validation of the 5-item short form of the Mishel Uncertainty in Illness Scale. European Journal of Oncology Nursing. 1-7.
  • Show author(s) (2014). Estradiol determines the effects of PTH on ERα-dependent transcription in MC3T3-E1 cells. Biochemical and Biophysical Research Communications - BBRC. 360-365.
  • Show author(s) (2013). cAMP response element-binding protein interacts with and stimulates the proteasomal degradation of the nuclear receptor coactivator GRIP1. Endocrinology. 1513-1527.
  • Show author(s) (2013). Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment. Breast Cancer Research and Treatment. 243-248.
  • Show author(s) (2013). A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Research. 11 pages.
  • Show author(s) (2013). 1,25-dihydroxyvitamin D and the vitamin D receptor gene polymorphism apa1 influence bone mineral density in primary hyperparathyroidism. PLOS ONE. 8 pages.
  • Show author(s) (2012). Vitamin B6 status and interferon-γ-mediated immune activation in primary hyperparathyroidism. Journal of Internal Medicine. 583-591.
  • Show author(s) (2012). Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide. Breast Cancer Research and Treatment. 693-700.
  • Show author(s) (2012). Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer. BMC Cancer. 12 pages.
  • Show author(s) (2011). Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Annals of Oncology. 582-587.
  • Show author(s) (2011). Primary hyperparathyroidism influences the expression of inflammatory and metabolic genes in adipose tissue. PLOS ONE. 10 pages.
  • Show author(s) (2011). Grapefruit juice and licorice increase cortisol availability in patients with Addison's disease. European Journal of Endocrinology (EJE). 761-769.
  • Show author(s) (2010). Seasonal and age-related differences in serum 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and parathyroid hormone in patients from Western Norway. Scandinavian Journal of Clinical and Laboratory Investigation. 281-286.
  • Show author(s) (2010). Effect of low-dose tamoxifen on steroid receptor coactivator 3/amplified in breast cancer 1 in normal and malignant human breast tissue. Clinical Cancer Research. 2176-2186.
  • Show author(s) (2010). Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 13 pages.
  • Show author(s) (2009). Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. Journal of Clinical Oncology. 3749-3756.
  • Show author(s) (2009). Randomized Biomarker Trial of Anastrozole or Low-Dose Tamoxifen or Their Combination in Subjects with Breast Intraepithelial Neoplasia. Clinical Cancer Research. 7053-7060.
  • Show author(s) (2009). Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer. 1253-1260.
  • Show author(s) (2009). Genotype-guided tamoxifen therapy: time to pause for reflection? The Lancet Oncology. 825-833.
  • Show author(s) (2008). Tamoxifen impairs both longitudinal and cortical bone growth in young male rats. Journal of Bone and Mineral Research. 1267-1277.
  • Show author(s) (2008). Recruitment of coactivator glucocorticoid receptor interacting protein 1 to an estrogen receptor transcription complex is regulated by the 3',5'-cyclic adenosine 5'-monophosphate-dependent protein kinase. Endocrinology. 4336-4345.
  • Show author(s) (2008). Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene copy number on tamoxifen metabolism. Annals of Oncology. 56-61.
  • Show author(s) (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment. Breast Cancer Research and Treatment. S144-S144.
  • Show author(s) (2006). Pretreatment with tamoxifen does not change acute epirubicin cardiotoxicity in rats. Basic & Clinical Pharmacology & Toxicology. 231-234.
  • Show author(s) (2006). Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 2968-75.
  • Show author(s) (2005). Induction of hepatic drug-metabolising enzymes and tamoxifen metabolite profile in relation to administration route during low-dose treatment in nude rats. Journal of Steroid Biochemistry and Molecular Biology. 489-498.
  • Show author(s) (2005). Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. Journal of Chromatography A. 6-14.
  • Show author(s) (2005). Excretion of hydroxylated metabolites of tamoxifen in human bile and urine. Anticancer Research. 4487-4492.
  • Show author(s) (2004). cAMP-dependent protein kinase regulates ubiquitin-proteasome-mediated degradation and subcellular localization of the nuclear receptor coactivator GRIP1. Journal of Biological Chemistry. 49120-49130.
  • Show author(s) (2004). Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in randomized preoperative trial. Clinical Cancer Research. 2336-2343.
  • Show author(s) (2004). Phenotypic expression of the methylenetetrahydrofolate reductase 677C->T polymorphism and flavine cofactor availability in thyroid dysfunction. American Journal of Clinical Nutrition. 1050-1057.
  • Show author(s) (2004). Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation. Arteriosclerosis, Thrombosis and Vascular Biology. 301-307.
  • Show author(s) (2003). Tamoxifen administration and metabolism in nude mice and nude rats. Journal of Steroid Biochemistry and Molecular Biology. 361-367.
  • Show author(s) (2003). Homocysteine and its relations to B-vitamins and smoking in graves' disease before and after treatment. Journal of Internal Medicine. 504-512.
  • Show author(s) (2003). Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healty women. Journal of Thrombosis and Haemostasis. 2149-2152.
  • Show author(s) (2003). Determination of choline, betaine, and dimethylglycine in plasma by a high-troughput metod based on normal-phase chromatography-tandem mass spectrometry. Clinical Chemistry. 286-294.
  • Show author(s) (2003). Characterization of receptor-interacting protein RIP140 in the regulation of SF-1 responsive target genes. Molecular and Cellular Endocrinology. 91-103.
  • Show author(s) (2003). A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. Journal of the National Cancer Institute. 779-790.
  • Show author(s) (2002). Tyreotoksisk periodisk paralyse - en uvanlig komplikasjon ved hypertyreose. Tidsskrift for Den norske legeforening. 1029-1031.
  • Show author(s) (2002). Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. European Journal of Endocrinology (EJE). 583-589.
  • Show author(s) (2001). Smoking, folate and methylenetetrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. American Journal of Medical Genetics. 246-254.
  • Show author(s) (2001). Plasma total homocysteine in hyper- and hypothyroid patients before and during 12 months of treatment. Clinical Chemistry. 1738-1741.
  • Show author(s) (2001). Effect of low dose tamoxifen on the insulin-like growth factor system in healthy women. Breast Cancer Research and Treatment. 21-27.
  • Show author(s) (2001). Correlation between tamoxifen elimination and biomarker recovery in a primary prevention trial. Cancer Epidemiology, Biomarkers and Prevention. 967-970.
  • Show author(s) (2000). Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
  • Show author(s) (2000). Selective oestrogen receptor modifiers (SERMs) and breast cancer therapy. Cancer Treatment Reviews. 205-227.
  • Show author(s) (2000). Plasma total homocysteine levels during short-term iatrogenic hypothyreoidism. Journal of Clinical Endocrinology and Metabolism (JCEM). 1049-1053.
  • Show author(s) (1999). Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters. 73-77.
  • Show author(s) (1999). Influence of aromatase inhibitors on plasma total homocysteine levels in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
  • Show author(s) (1999). Influence of aromatase inhibitors on plasma total homocysteine in postmenopausal breast cancer patients. Clinical Chemistry. 252-256.
  • Show author(s) (1999). Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction. Journal of Clinical Oncology. 2633-2688.
  • Show author(s) (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Show author(s) (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Show author(s) (1998). Thyroid function in postmenopausal breast cancer patients treated with tamoxifen. Scandinavian Journal of Clinical and Laboratory Investigation. 103-107.
  • Show author(s) (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
  • Show author(s) (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
  • Show author(s) (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
  • Show author(s) (1998). Plasma total homocysteine levels in hyperthyroid and hypothyroid patients. Metabolism: Clinical and Experimental. 89-93.
  • Show author(s) (1997). Treatment of small cell lung cancer (SCLC) with high dose tamoxifen in combination with epirubicin, cyclophosphamide and oncovin. European Journal of Clinical Pharmacology. 102.
  • Show author(s) (1997). Effects of hormones on the plasma levels of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Show author(s) (1997). Effects of hormones on the plasma level of the atherogenic amino acid homocysteine. Biochemical Society Transactions. 33-35.
  • Show author(s) (1995). Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • Show author(s) (1995). Relations between sex hormones, sex hormone binding globulin insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clinical Endocrinology. 23-30.
  • Show author(s) (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Show author(s) (1995). Plasma levels of the atherogenic amino acid homocysteine in post-menopausal women with breast cancer treated with tamoxifen. International Journal of Cancer. 365-368.
  • Show author(s) (1995). Pharmacokinetics of tamoxifen in pre- and post-menopausal women with breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 229-231.
  • Show author(s) (1995). Influence of tamoxifen on sex hormones, gonadotropins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Show author(s) (1995). Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 491-496.
  • Show author(s) (1995). Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • Show author(s) (1995). Determination of droloxifene and two metabolites in serum by high pressure liquid chromatography. Therapeutic Drug Monitoring. 259-265.
  • Show author(s) (1994). Pharmacokinetics of anti-endocrine agents. Cancer Surveys. S. 343-370.
  • Show author(s) (1994). High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology. 79-83.
  • Show author(s) (1992). Intermittent high dose tamoxifen as a potential modifier of multi-drug resistance. European Journal of Cancer. 805-810.
  • Show author(s) (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Show author(s) (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Show author(s) (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Show author(s) (1992). Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-1 levels in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 541-543.
  • Show author(s) (1992). Influence of tamoxifen on plasma levels of insulinelike growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • Show author(s) (1992). Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research. 4719-4723.
  • Show author(s) (1992). Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • Show author(s) (1992). Influence of tamoxifen on plasma levels of IGF-I and IGFBP-I in breast cancer patients. Cancer Research. 4719-4723.
  • Show author(s) (1992). High dose tamoxifen as an enhancer of etoposide cytotoxicity.Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. British Journal of Cancer. 833-839.
  • Show author(s) (1991). Distribution of tamoxifen and metabolites into brain tissue metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • Show author(s) (1991). Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. British Journal of Cancer. 641-645.
  • Show author(s) (1991). Distribution of tamoxifen and its metabolites in tissues of rat and man during steady state treatment. Cancer Research. 4837-4844.
  • Show author(s) (1991). Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Cancer Research. 4837-4844.
  • Show author(s) (1991). Distribution of Tamoxifen and meta-bolites into brain tissue and brain metastases in brain cancer patients. British Journal of Cancer. 641-645.
  • Show author(s) (1990). Decreased serum concentrations of tamoxifen and its metabolites induced by aminogluethimide. Cancer Research. 5851-5857.
Academic lecture
  • Show author(s) (2005). Distribution of tamoxifen in serum and breast cancer tissue and its effects on sex hormone-binding globulin (SHBG).
  • Show author(s) (2004). Pharmacokinetics and pharmacodynamics of tamoxifen.
  • Show author(s) (2002). Steroidogenesis - Role of Steroidogenic factor-1 and interacting nuclear receptor coregulators.
  • Show author(s) (2001). Smoking, folate, and MTHFR C677T genotype as interactive determinants of adenomatous and hyperplastic polyps of colorectum.
  • Show author(s) (2001). Homocysteine and thyroid function.
  • Show author(s) (2000). Correlation between tamoxifen elimination and biomarker recovery in a promary prevention trial.
  • Show author(s) (1999). Plasma levels of homocysteine are changed during treatment of hyper- and hypothyroidism.
  • Show author(s) (1997). Phase 1 and pharmacokinetic study of high dose tamoxifen combined with epirubicin, cyclophosphamide and oncovin.
Reader opinion piece
  • Show author(s) (2013). Breaking away: High fracture rates may merit a new trial of adjuvant endocrine therapy in Scandinavian breast cancer patients. Acta Oncologica. 861-U216.
  • Show author(s) (2004). Letter. Journal of the National Cancer Institute. 883-883.
  • Show author(s) (2001). Total plasma homocysteine in hypo- and hyperthyroidism: Covariations and causality. Journal of Clinical Endocrinology and Metabolism (JCEM). 1846.
Doctoral dissertation
  • Show author(s) (2007). Nuclear Receptor Coregulators- Role of Protein-Protein Interactions and cAMP/PKA Signaling.
  • Show author(s) (2007). Betaine and its relation to homocysteine status and one-carbon metabolism in humans : analytical method and biochemical studies.
  • Show author(s) (2004). Pharmacology of low-dose tamoxifen regimens in breast cancer treatment.
  • Show author(s) (2004). Graves' disease and hypothyroidism with emphasis on treatment, homocysteine and B-vitamins.
  • Show author(s) (1991). Tamoxifen pharmacokinetics in breast cancer patients. Analytical methods, pharmacokinetics, tissue distribution and drug interactions. (dr.med.).
Documentary
  • Show author(s) (2004). "En hormonell kriminalhistorie".
Academic chapter/article/Conference paper
  • Show author(s) (2012). Tamoxifen metabolism and biological activity. 22 pages.
  • Show author(s) (2011). Steroid Receptor Coactivators and Their Expression, Regulation and Functional Role in Endocrine Responsive and Resistant Breast Cancer. 18 pages.
  • Show author(s) (2011). Steroid Receptor Coactivators and Endocrine Treatment in Breast Cancer. 32 pages.
  • Show author(s) (1999). Hormoner og hormonantagonister. 15 pages.
  • Show author(s) (1998). Legemiddelanalyser og rusmiddelanalyser. 8 pages.
  • Show author(s) (1994). Utprøving av dataprogrammet "Aldus Persuasion" og "Davis Transview Presenter" som hjelpemidler i forberedelse og gjennomføring av undervisning. 10 pages.
  • Show author(s) (1991). Tamoxifen uptake in brain tissue and brain metastases in man.
Abstract
  • Show author(s) (2013). Associations between tamoxifen and age during steady state tamoxifen treatment of postmenopausal women with breast cancer. Experimental and clinical endocrinology & diabetes. 1 pages.
  • Show author(s) (2010). Grapefruit and Liquorice Increase Bioavailable Cortisol in Addison's Disease. Endocrine reviews. 1 pages.
  • Show author(s) (2010). Effects of CYP2C19 genotype on tamoxifen and estrogen metabolism. European Journal of Cancer. 60-60.
  • Show author(s) (2009). Ki-67 Expression after Tamoxifen Given Preoperatively Predicts Disease Free Survival and Overall Survival in Women with Operable ER-Positive Breast Cancer. Cancer Research. 517S-518S.
  • Show author(s) (2008). Vitamin D-metabolism and PTH levels show a biphasic seasonal pattern but are not correlated to osteocalcin levels in outpatients from western Norway. Calcified Tissue International. S150-S151.
  • Show author(s) (2008). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 592-592.
  • Show author(s) (2007). Effect of CYP2D6 and SULT1A1 genotypes on the serum concentration of 4-hydroxytamoxifen and 4-hydroxy-N-demethyltamoxifen during steady state treatment of breast cancer patients. Breast. S15-S15.
  • Show author(s) (2007). A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment.
  • Show author(s) (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients. Breast Cancer Research and Treatment. S236-S237.
Poster
  • Show author(s) (2018). A prospective, longitudinal, breast cancer biobank (PBCB) in western Norway.
  • Show author(s) (2013). Vitamin D levels in patients with primary hyperparathyroidism; a follow-up study after parathyroidectomy.
  • Show author(s) (2012). Systemic Inflammation in Primary Hyperparathyroidism: Influences on Plasma Vitamin B6 Levels and Interferon-γ Mediated Immune Activation.
  • Show author(s) (2011). Differential Expression of Inflammatory and Metabolic Genes in Adipose Tissue of Patients with Primary Huperparathyroidism.
  • Show author(s) (2010). Expression of Steroid Receptor Coactivators and HER-2/neu in normal and malignant breast tissue in controls and tamoxifen treated patients.
  • Show author(s) (2009). The Role of PKA and CREB in regulation of the Steroid Receptor Coactivator GRIP1/SRC-2.
  • Show author(s) (2009). Relations between FSH, SHBG and tamoxifen metabolism during steady state tamoxifen treatment.
  • Show author(s) (2009). PTH inhibits ligand-dependent activation of estrogen receptor alfa in MC3T3 osteoblasts.
  • Show author(s) (2009). PTH inhibits ligand-dependent activation of estrogen receptor alfa in MC3T3 Osteoblasts.
  • Show author(s) (2009). HER-2/neu and nuclear receptor coactivators are upregulated in breast cancer tumors during estrogen deprivation.
  • Show author(s) (2008). Changes in mRNA expression levels of steroid receptor coactivators correlate with treatment response to aromatase inhibition in human breast cancer.
  • Show author(s) (2007). Effect of CYP2D6 and SULT1A1 Genotypes on the serum concentration of 4-OHtamoxifen and 4-OH-N-Demethyltamoxifen during steady state treatment of breast cancer patients.
  • Show author(s) (2007). A study of association between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferae 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady sate tamoxifen treatment.
  • Show author(s) (2006). ROLES OF cAMP RESPONSE ELEMENT BINDING PROTEIN (CREB) IN REGULATION OF GLUCOCORTICOID RECEPTOR INTERACTING PROTEIN 1 (GRIP1).
  • Show author(s) (2005). Relationship between CYP2D6 and SULT1A1 genotypes and serum concentrations of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
  • Show author(s) (2005). Relationship between CYP2D6 and SULT1A1 genotype and serum concentration of tamoxifen and its metabolites during steady state treatment in breast cancer patients.
  • Show author(s) (2005). Effects of low-dose tamoxifen treatment on expression of drug-metabolising enzymes in rat liver in relation to administration route.
  • Show author(s) (2005). CHARACTERIZATION OF THE MOLECULAR MECHANISMS BY WHICH THE LEVEL OF NUCLEAR HORMONE RECEPTOR COACTIVATOR GRIP1 IS REGULATED.
  • Show author(s) (2004). Tamoxifen metabolism and induction of hepatic drug-metabolizing enzymes in nude rats.
  • Show author(s) (2004). Quantification of serum tamoxifen and metabolites by liquid chromatography-tandem mass spectrometry.
  • Show author(s) (2002). Tamoxifen metabolism in immunocompromised rats and mice.
  • Show author(s) (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor–1.
  • Show author(s) (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor-1.
  • Show author(s) (2001). Receptor Interacting Protein RIP140 inhibits transcriptional activity of Steroidogenic factor-1.
  • Show author(s) (2001). Plasma levels of homocysteine are changed during treatment of hyper- and hypo-thyroidism.
  • Show author(s) (2001). A comparative study of tamoxifen metabolism in immunodeficient rats and nude mice.
  • Show author(s) (2001). A comparative study of tamoxifen metabolism in immunodeficient nude rats and nude mice.
Article in business/trade/industry journal
  • Show author(s) (2022). Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study. BMJ Open.

More information in national current research information system (CRIStin)